- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
Novo Nordisk A/S to Discuss Rybelsus® US Approval Call Transcript
Ladies and gentlemen, thank you for standing by, and welcome to the investor call following the approval of Rybelsus in the U.S.A. (Operator Instructions) After the speaker presentation, there will be a question-and-answer session. (Operator Instructions) I must advise you that today's call is being recorded, Monday, the 23rd of September 2019.
And I should now hand over to your speaker for today, Karsten Munk Knudsen. Please go ahead.
/-&
Thank you. Welcome to this Novo Nordisk's conference call regarding the regulatory approval of Rybelsus in the U.S. I'm Karsten Munk Knudsen, the CFO of Novo Nordisk. With me, I have our Chief Science Officer, Mads Krogsgaard Thomsen. Present are also our Investor Relations officers. Today's conference call and slides are available on our website, novonordisk.com. The conference call is scheduled to last 30 minutes. We will start with a brief presentation followed by a Q&A session beginning in about 10
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |